A randomised, double‐blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO‐524 in dogs with atopic dermatitis

Abstract

BackgroundPolyunsaturated fatty acids (PUFA) can be beneficial in the management of canine atopic dermatitis (cAD). A commercial product PCSO‐524 containing PUFA has demonstrated anti‐inflammatory effects in dogs.Hypothesis/ObjectivesTo evaluate the efficacy of PCSO‐524, in combination with oclacitinib in dogs with cAD.AnimalsSeventeen client‐owned dogs with cAD.Materials and MethodsA randomised, double‐blinded, controlled trial. All dogs were treated with oclacitinib (0.4–0.6 mg/kg) twice a day for 14 days, then once a day until Day (D)42. They were randomly divided into two groups: PCSO‐524 (n = 9) and sunflower oil (n = 8). Clinical status was assessed by Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI‐04) and pruritus Visual Analog Scale (pVAS) at baseline (D0), D14, D28 and D42. Trans epidermal water loss (TEWL) was measured at the same time points.ResultsCADESI scores decreased significantly after treatment and there was a significant difference between the PCSO‐524 and the control group at D28 (p = 0.04) and D42 (p = 0.03). The PCSO‐524 group also demonstrated a significantly decreased pVAS on D28 and D42 (p < 0.001 and p < 0.001) compared to D0, while significant differences were observed in the control group at D14 and D28 (p < 0.01 and p = 0.04) and not at D42 (p = 0.12). The mean TEWL showed a significant decrease at D28 and D42 in the PCSO‐524 group, compared to the control group (p = 0.002 and p < 0.001).Conclusions and Clinical RelevanceThe combination of PCSO‐524 and oclacitinib may help to alleviate the rebound effect that occurs when tapering down the dosage of oclacitinib, as compared to using oclacitinib alone for the management of cAD.